Infectious Mononucleosis (Epstein-Barr Virus)

Virus/Defining Trait

EBV = HHV-4, herpesvirus. Latency, but UNIQUE: B LYMPHOCYTES (not sensory neurons like HSV/VZV). gp350 (viral envelope) binds CD21/CR2 on B cells. B-cell tropism explains EVERYTHING clinically distinctive.

Transmission/Pathogenesis

SALIVA (“kissing disease”). Oropharyngeal epithelium → B lymphocytes → disseminates. EBV drives B cell POLYCLONAL PROLIFERATION/activation. Host CD8+ CYTOTOXIC T-CELL response to this = produces disease findings. KEY POINT: “ATYPICAL LYMPHOCYTES” on smear = REACTIVE CYTOTOXIC T CELLS (responding to infection), NOT the infected B cells themselves — commonly misunderstood.

Clinical Manifestations

Age at first infection PREDICTS presentation: Early childhood: mild/asymptomatic. Adolescence/young adulthood (delayed by better childhood hygiene): CLASSIC infectious mononucleosis — fever, severe pharyngitis (thick grey-white exudate, mimics strep/diphtheria), PROMINENT generalized LAD (classically posterior cervical, broader than rubella’s specific pattern), SPLENOMEGALY (substantial proportion).

Splenomegaly consequence: SPLENIC RUPTURE risk (uncommon but real) — activity restriction (contact sports) for weeks during illness/recovery.

KEY TESTABLE PITFALL: AMPICILLIN/AMOXICILLIN (mistaken strep pharyngitis Rx) → DIFFUSE MORBILLIFORM RASH in large majority of mono patients. NOT TRUE PENICILLIN ALLERGY — EBV-specific hypersensitivity to aminopenicillins. Mislabeling as allergy has real downstream consequences for future antibiotic choice.

Chronic/malignant associations (EBV, HBV, H. pylori = clearest IARC-recognized infectious-cancer examples in curriculum):

Burkitt lymphoma — esp. endemic African form, linked to holoendemic MALARIA co-infection (impairs EBV-specific T-cell control)
Nasopharyngeal carcinoma — striking geographic concentration S. China/SE Asia (EBV + genetic/dietary cofactors)
PTLD (Post-Transplant Lymphoproliferative Disease) — transplant recipients, iatrogenic immunosuppression removes T-cell control of EBV-driven B-cell proliferation → lymphoproliferative malignancy. Direct illustration: CMI-controls-latent-virus principle (Immune Response topic), malignancy = consequence of LOSING control.

Laboratory Diagnosis

Heterophile Ab test (Monospot/Paul-Bunnell): cross-reacts/agglutinates sheep/horse RBC (heterophile = unrelated antigen cross-reactivity, no actual EBV specificity). Classic rapid screen, positive MAJORITY adolescent/adult cases. LESS RELIABLE in YOUNG CHILDREN (often fail heterophile response despite confirmed infection) — remember when negative in young child with compatible picture.

EBV-specific serology: VCA-IgM (acute), VCA-IgG + EBNA (past infection, EBNA takes WEEKS to develop → distinguishes recent from long-past). MORE SPECIFIC, preferred in young children/heterophile-negative cases.

Peripheral smear: atypical (reactive) lymphocytes support diagnosis. Mild transaminitis: common nonspecific supportive finding.

Treatment

NO specific antiviral. ENTIRELY SUPPORTIVE (rest, hydration, analgesia/antipyretics). Activity restriction (splenic rupture risk). Corticosteroids: ONLY specific severe complications (significant airway obstruction from tonsillar swelling, severe hemolytic anemia) — NOT routine uncomplicated disease.

The Virus and Its Defining Biological Trait

Epstein-Barr virus (EBV), a human herpesvirus (HHV-4), shares the herpesvirus family’s defining latency property covered in depth under Herpes Simplex and Varicella-Zoster Virus Infections, but with a genuinely distinctive twist: rather than establishing latency in sensory neurons the way HSV/VZV do, EBV establishes lifelong latency specifically in B lymphocytes, which it infects via the viral envelope glycoprotein gp350 binding CD21 (the complement receptor CR2) on the B-cell surface — this specific B-cell tropism is the single fact that explains nearly everything distinctive about EBV’s clinical behaviour, from infectious mononucleosis’s characteristic lymphocyte findings through to the organism’s genuinely notable, well-documented role in several B-cell malignancies (below).

Transmission and Pathogenesis

Transmission is via saliva (the informal name “kissing disease” reflects this route directly), with the virus replicating initially in oropharyngeal epithelium before infecting B lymphocytes and disseminating. Once EBV infects a B cell, it drives that cell into polyclonal B-cell proliferation and activation — and the host’s cell-mediated immune response to this EBV-driven B-cell proliferation, chiefly a vigorous CD8+ cytotoxic T-cell response against EBV-infected B cells, is what actually produces the disease’s characteristic clinical and laboratory findings: the “atypical lymphocytes” seen on a peripheral blood smear in infectious mononucleosis are not the infected B cells themselves but rather these reactive cytotoxic T cells, responding to and controlling the B-cell infection — a genuinely important point often missed, since the disease’s name and lymphocyte findings can misleadingly suggest the atypical cells are the infected/malignant population, when they are actually the host’s own defending immune cells.

Clinical Manifestations

Age at first infection strongly predicts clinical presentation, a pattern worth understanding as the central organizing fact of this topic’s clinical section: infection in early childhood is typically mild or entirely asymptomatic, while infection delayed until adolescence or young adulthood (a demographic shift genuinely common in higher-resource settings with better childhood hygiene, paradoxically delaying rather than preventing infection) produces the classic, full infectious mononucleosis syndrome — fever, severe pharyngitis (often with a thick, grey-white tonsillar exudate that can closely resemble streptococcal or diphtheritic exudate), and prominent, often generalized lymphadenopathy (classically posterior cervical, though genuinely more widespread than the specific posterior-auricular/suboccipital pattern covered under Rubella), together with splenomegaly in a substantial proportion of cases — a finding with real, specific clinical consequence, since splenic enlargement carries a genuine, if uncommon, risk of splenic rupture, which is exactly why contact sports and other activities risking abdominal trauma are specifically restricted for several weeks during acute illness and recovery.

A genuinely important, specifically testable clinical pitfall: infectious mononucleosis patients given ampicillin or amoxicillin (mistakenly treated for presumed streptococcal pharyngitis, given the exudative sore throat’s clinical overlap) very commonly develop a diffuse morbilliform rash — this is not a true penicillin allergy but rather a specific, EBV-infection-associated hypersensitivity-type reaction to aminopenicillins, occurring in a large majority of mononucleosis patients given these specific antibiotics, and it is a genuinely important point to know precisely, since mislabelling this reaction as a true penicillin allergy has real, lasting downstream consequences for that patient’s future antibiotic choices if the distinction isn’t made clear at the time.

Chronic and malignant associations: EBV is genuinely notable, alongside HBV and H. pylori (covered under their own topics), as one of the clearest examples in this curriculum of an infectious agent with a well-documented, IARC-recognized role in specific human cancers — Burkitt lymphoma (particularly the endemic African form, strongly EBV-associated, and classically linked to holoendemic malaria co-infection, which is thought to impair EBV-specific T-cell control and permit the B-cell proliferation to progress toward malignant transformation), nasopharyngeal carcinoma (with a genuinely striking geographic concentration in Southern China and Southeast Asia, reflecting a combination of EBV infection with additional genetic and dietary/environmental cofactors), and post-transplant lymphoproliferative disease (PTLD) — a genuinely important, specifically relevant complication in solid organ/haematopoietic stem cell transplant recipients, where the iatrogenic immunosuppression needed to prevent graft rejection simultaneously removes the T-cell control that normally keeps EBV-driven B-cell proliferation in check, allowing it to progress toward a genuine, sometimes aggressive lymphoproliferative malignancy — a direct, mechanistic illustration of the same CMI-controls-latent-virus principle covered generally under Immune Response, here with malignancy as the consequence of losing that control rather than simple reactivation.

Laboratory Diagnosis

Heterophile antibody test (Monospot/Paul-Bunnell test) — detecting a specific class of antibody that, genuinely notably, cross-reacts with and agglutinates sheep or horse red blood cells despite having no actual specificity for EBV itself (a heterophile antibody, by definition, reacting with an antigen unrelated to the one that induced it) — is the classic, rapid, widely used screening test, positive in the substantial majority of adolescent/adult cases but genuinely less reliable in young children, who often fail to mount a detectable heterophile response even with confirmed EBV infection, a real, specific limitation worth remembering when the test comes back negative in a young child with a compatible clinical picture. EBV-specific serology (antibodies against viral capsid antigen, VCA-IgM for acute infection, VCA-IgG and EBNA — Epstein-Barr nuclear antigen — for past infection, the EBNA response specifically taking weeks to develop and therefore useful for distinguishing recent from long-past infection) is more specific and is the preferred confirmatory approach, particularly in young children or heterophile-negative cases. Peripheral blood smear showing the atypical (reactive) lymphocytes described above supports the diagnosis, and mild transaminitis (elevated liver enzymes, reflecting mild hepatic involvement) is a common, nonspecific supportive laboratory finding.

Treatment

There is no specific antiviral treatment for uncomplicated infectious mononucleosis — management is entirely supportive (rest, hydration, analgesia/antipyretics), with activity restriction specifically to reduce splenic rupture risk as described above. Corticosteroids have a role only in specific, severe complications (significant airway obstruction from tonsillar swelling, severe haemolytic anaemia, or other genuinely severe manifestations), not for routine, uncomplicated disease.